ArticleFrontiers in public health2025
Association between polycyclic aromatic hydrocarbons exposure and metabolic dysfunction-associated steatotic liver disease in US adults.
Article in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the individual or combined effects of polycyclic aromatic hydrocarbons (PAHs) on metabolic dysfunction-associated steatotic liver disease (MASLD) in U.S. adults. Methods: We enrolled 3,130 participants aged 20 and over from the 2007-2016 National Health and Nutrition Examination Survey (NHANES) and analyzed six urinary PAH metabolites. The Poisson regression, Bayesian kernel machine regression (BKMR), and weighted quantile sum (WQS) regression models were used to assess the associations between PAHs and MASLD. Results: After adjusting for covariates, Poisson regression model showed significant associations [ Conclusion: This study suggests that exposure to PAHs, individually or in combination, may be associated with an increased risk of MASLD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.